Outpace (often referred to as Outpace Bio) is a biotechnology company focused on engineering more effective and precise cell and protein therapies for serious diseases, particularly in the area of immuno-oncology. Below is an overview of who they are and what they do:

1. Core Mission
• Outpace’s central goal is to “outpace disease” by developing next-generation tools to engineer immune cells so they can better recognize and attack cancer or other difficult-to-treat diseases.
2. Technology & Approach
• Protein Engineering: Outpace employs sophisticated protein design techniques—often leveraging computational methods—to create custom proteins and molecular “switches” that give therapeutic cells new or enhanced functions.
• Cell Therapy: Their work extends to advanced cell therapy platforms (e.g., T-cell therapies) that incorporate these engineered proteins, potentially making treatments more potent, durable, and safer.
• Synthetic Biology: By applying synthetic biology principles, Outpace aims to program cells with new sensing and response behaviors, effectively “rewiring” immune cells to mount more coordinated, precise attacks against tumors or other targets.
3. Therapeutic Focus
• While Outpace’s technologies can have broad applications, much of its initial focus is on cancer immunotherapy. The company aims to create therapies that overcome existing limitations, such as immune evasion or toxicity, by building “smart” therapeutic cells that adapt in real time.
4. Team & Expertise
• Outpace’s leadership and scientific teams bring together experts across protein engineering, computational biology, immunology, and cell therapy. This multidisciplinary approach is central to rapidly moving from concept to clinic.
5. Partnerships & Pipeline
• In addition to developing its own pipeline, Outpace collaborates with other biotechnology and pharmaceutical companies. By offering its cell engineering platform, Outpace can help partners incorporate advanced synthetic biology tools into next-generation therapies.

Overall, Outpace is combining state-of-the-art protein engineering, synthetic biology, and immunology to create safer, more effective engineered cell therapies. The goal is to offer novel treatment options that significantly improve patient outcomes in oncology and beyond.